U.S. Markets closed
  • S&P Futures

    4,697.50
    +12.50 (+0.27%)
     
  • Dow Futures

    35,770.00
    +57.00 (+0.16%)
     
  • Nasdaq Futures

    16,379.50
    +61.50 (+0.38%)
     
  • Russell 2000 Futures

    2,262.20
    +8.30 (+0.37%)
     
  • Crude Oil

    71.78
    -0.27 (-0.37%)
     
  • Gold

    1,789.80
    +5.10 (+0.29%)
     
  • Silver

    22.53
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1285
    +0.0013 (+0.1129%)
     
  • 10-Yr Bond

    1.4800
    +0.0320 (+2.21%)
     
  • Vix

    21.89
    -6.06 (-21.68%)
     
  • GBP/USD

    1.3249
    +0.0008 (+0.0570%)
     
  • USD/JPY

    113.4950
    -0.0450 (-0.0396%)
     
  • BTC-USD

    50,559.64
    -177.46 (-0.35%)
     
  • CMC Crypto 200

    1,308.72
    -133.04 (-9.23%)
     
  • FTSE 100

    7,339.90
    +210.69 (+2.96%)
     
  • Nikkei 225

    28,768.39
    +312.79 (+1.10%)
     

Here's Why We're Not Too Worried About Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Situation

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

Given this risk, we thought we'd take a look at whether Connect Biopharma Holdings (NASDAQ:CNTB) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.

See our latest analysis for Connect Biopharma Holdings

Does Connect Biopharma Holdings Have A Long Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In June 2021, Connect Biopharma Holdings had CN¥2.0b in cash, and was debt-free. Looking at the last year, the company burnt through CN¥405m. Therefore, from June 2021 it had 5.0 years of cash runway. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Connect Biopharma Holdings' Cash Burn Changing Over Time?

Because Connect Biopharma Holdings isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. In fact, it ramped its spending strongly over the last year, increasing cash burn by 196%. With spending growing that quickly, shareholders will be hoping that the money is prudently spent. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Connect Biopharma Holdings To Raise More Cash For Growth?

While Connect Biopharma Holdings does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of CN¥8.1b, Connect Biopharma Holdings' CN¥405m in cash burn equates to about 5.0% of its market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

So, Should We Worry About Connect Biopharma Holdings' Cash Burn?

It may already be apparent to you that we're relatively comfortable with the way Connect Biopharma Holdings is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. While we must concede that its increasing cash burn is a bit worrying, the other factors mentioned in this article provide great comfort when it comes to the cash burn. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. Taking a deeper dive, we've spotted 4 warning signs for Connect Biopharma Holdings you should be aware of, and 2 of them are significant.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.